parkinson’s disease
-
alpha-synuclein, ambroxol, biomarker, Brain, exenatide, exercise, GLP-1 agonist, Neurodegenerative Diseases, parkinson’s disease, Prevention, prodromal, Psychology, RBD, REM sleep behavior disorder, sleepParkinson’s Disease Prevention: Prodromal Symptoms, RBD, Early Intervention Trials
Parkinson’s disease has a years-to-decades prodromal stage where motor symptoms haven’t yet…
-
exenatide, GLP-1, lixisenatide, network meta-analysis, Neurodegenerative Diseases, neurology, neuroprotection, neuroscience, Ozempic, parkinson’s diseaseCan GLP-1 Drugs Slow Parkinson’s Disease? Evidence from 5 Trials
Research Highlights GLP-1 receptor agonists are diabetes drugs (Ozempic, Trulicity, Byetta) being…
-
bdnf, bdnf gene, dopamine, dopamine neurons, Drugs, gene therapy, genetics, motor behavior, motor symptoms, Neurodegenerative Diseases, parkinson’s disease, pramiprexole, transfectionBDNF Gene Transfection & Pramiprexole Combo Effectively Treat Parkinson’s Disease in Rat Models (2024 Study)
Parkinson’s disease (PD), a degenerative disorder that predominantly affects the motor system,…
